PL396354A1 - Sposób otrzymywania amorficznego indapamidu - Google Patents
Sposób otrzymywania amorficznego indapamiduInfo
- Publication number
- PL396354A1 PL396354A1 PL396354A PL39635411A PL396354A1 PL 396354 A1 PL396354 A1 PL 396354A1 PL 396354 A PL396354 A PL 396354A PL 39635411 A PL39635411 A PL 39635411A PL 396354 A1 PL396354 A1 PL 396354A1
- Authority
- PL
- Poland
- Prior art keywords
- indapamide
- obtaining amorphous
- amorphous
- obtaining
- amorphization
- Prior art date
Links
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004569 indapamide Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- GPFKQEHXQLDCEK-UHFFFAOYSA-N 4-chloro-n-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide;hydrate Chemical compound O.CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1.CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 GPFKQEHXQLDCEK-UHFFFAOYSA-N 0.000 abstract 1
- 238000005280 amorphization Methods 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940127088 antihypertensive drug Drugs 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem wynalazku jest sposób otrzymywania amorficznego indapamidu o wzorze ogólnym 1, stosowanego jako lek moczopędny a także obniżający ciśnienie tętnicze, charakteryzujący się tym, że materiał wyjściowy w postaci hydratu krystalicznego indapamidu umieszcza się w młynku kriogenicznym i poddaje mieleniu w temperaturze ciekłego azotu w czasie koniecznym do jego amorfizacji, zależnym od ilości mielonego materiału.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL396354A PL223244B1 (pl) | 2011-09-16 | 2011-09-16 | Sposób otrzymywania amorficznego indapamidu |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL396354A PL223244B1 (pl) | 2011-09-16 | 2011-09-16 | Sposób otrzymywania amorficznego indapamidu |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL396354A1 true PL396354A1 (pl) | 2013-03-18 |
| PL223244B1 PL223244B1 (pl) | 2016-10-31 |
Family
ID=47846475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL396354A PL223244B1 (pl) | 2011-09-16 | 2011-09-16 | Sposób otrzymywania amorficznego indapamidu |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL223244B1 (pl) |
-
2011
- 2011-09-16 PL PL396354A patent/PL223244B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL223244B1 (pl) | 2016-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07102A (pl) | ||
| NZ627586A (en) | Pyridone derivatives | |
| CL2012001348A1 (es) | Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry. | |
| EA201791066A1 (ru) | Твердые формы ингибитора ask1 | |
| MY162825A (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
| WO2012090043A8 (en) | Novel solid state forms of azilsartan medoxomil and preparation thereof | |
| HK1220355A1 (zh) | Mk2抑制劑和其用途 | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| EA201071291A3 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| MX2016008110A (es) | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. | |
| WO2013056684A3 (zh) | 作为dhodh抑制剂的噻唑衍生物及其应用 | |
| HUE036953T2 (hu) | 2,3-dihidro-benzo[1,4]oxazin-származékok és rokon vegyületek, mint foszfoinozitid-3-kináz (PI3K) inhibitorok például reumatoid arthritis kezelésére | |
| NZ724645A (en) | Pde10 inhibitors and related compositions and methods | |
| IN2014DN07101A (pl) | ||
| WO2012068441A3 (en) | Intedanib salts and solid state forms thereof | |
| MY205261A (en) | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | |
| PH12020550133A1 (en) | Crystal forms of immunomodulators | |
| NZ735736A (en) | Acetate salt of buprenorphine and methods for preparing buprenorphine | |
| MX369228B (es) | Revestimientos de geomembranas a altas temperaturas y composiciones de lote maestro. | |
| CY1121484T1 (el) | Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4 | |
| AR101368A1 (es) | Forma cristalina de sofosbuvir y proceso para su preparación | |
| NZ710600A (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| UY33305A (es) | Compuestos heterocíclicos inhibidores de DGAT1 | |
| NZ720340A (en) | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof | |
| CY1122140T1 (el) | Μεθοδος παραγωγης φαρμακολογικως καθαρων κρυσταλλων |